IceCure Medical’s ProSense® Shows Promising Trial Results
Company Announcements

IceCure Medical’s ProSense® Shows Promising Trial Results

Icecure Medical (ICCM) has released an update.

IceCure Medical’s ProSense® Cryoablation system has demonstrated a 96.3% recurrence-free rate in early-stage, low-risk breast cancer, offering a minimally invasive alternative to surgery with high patient and physician satisfaction regarding cosmetic outcomes. The results of the ICE3 trial, published in the Annals of Surgical Oncology, indicate the procedure’s safety and effectiveness, paving the way for potential FDA marketing authorization.

For further insights into ICCM stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskIceCure Medical’s ProSense® Gains FDA Panel Support
TheFlyIceCure Medical announces FDA’s favorable recommendation for ProSense
TipRanks Auto-Generated NewsdeskIceCure Medical Expands Patent Portfolio with New US Approval
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App